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Abstract:  While 25 compounds have been formally licensed for the treatment of HIV 
infection (AIDS), only seven licensed products are currently available for the treatment of 
chronic hepatitis B virus (HBV) infection: interferon-α, pegylated interferon-α, 
lamivudine, adefovir (dipivoxil), entecavir, telbivudine and tenofovir (disoproxil 
fumarate). In contrast to the treatment of HIV infections where the individual drugs are 
routinely used in combination, for the treatment of chronic HBV infection the individual 
drugs are generally used in monotherapy. In principle, combination drug therapy should 
allow reducing the likelihood of drug-resistant development. 
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Abbreviations 
3TC  -  Lamivudine  [(-)β-L-2’,3’-dideoxy-3’-thiacytidine] 
3TC-TP   -  3TC-triphosphate 
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CHB    -  Chronic Hepatitis B 
dCTP   -  Deoxycytidine  Triphosphate 
DDDP    -  Viral DNA - Dependent DNA Polymerase 
DHBV    -  Duck Hepatitis B Virus 
DR    -  Direct  Repeat 
dsl    -  double-stranded  linear 
EC50  -  50% Effective (inhibitory) Concentration 
FDA    -  Food and Drug Administration 
(-)FTC   -  Emtricitabine 
HBcAg    -  Hepatitis B core Antigen 
HBeAg    -  Hepatitis B e Antigen 
HBsAg    -  Hepatitis B surface Antigen 
HBV    -  (Human) Hepatitis B Virus 
HCC   - Hepatocellular  Carcinoma 
L-dT   - β-L-2’-deoxythymidine 
NNRTIs    -  Non-Nucleoside Reverse Transcriptase Inhibitors 
PEG-IFN   -  Pegylated  Interferon  α-2a 
pgRNA   -  pregenomic  RNA 
RC    -  Relaxed  Circular 
siRNAs    -  small interfering RNAs 
TDF    -  Tenofovir Disoproxil Fumarate 
WHV    -  Woodchuck Hepatitis Virus 
1. Introduction 
Chronic hepatitis B (CHB) can lead to life-threatening conditions like cirrhosis and hepatocellular 
carcinoma (HCC). Cirrhosis develops in approximately 20% of chronically infected patients, 
subsequently leading to hepatic insufficiency and portal hypertension [1]. Moreover, these patients 
have a 100-fold higher risk of developing hepatocellular carcinoma than non-carriers [2-4]. Hepatitis B 
excreted antigen (HBeAg) represents an important marker for HCC, since HBeAg-positive subjects are 
at highest risk of developing HCC [5]. In late stages of cirrhosis or HCC, liver transplantation is the 
only option left. Therefore, detection of HBV infection at an early stage and prompt treatment are of 
crucial importance. Indicators for a sustained virological response are clearance of HBeAg, 
seroconversion from HBeAg to corresponding anti-HBe antibodies, and a drop in circulating HBV 
DNA below detection level [1,6]. 
Seven drugs have been licensed by the United States FDA (Food and Drug Administration) for the 
treatment of CHB: interferon-alpha and pegylated interferon-alpha, three nucleoside analogs 
(lamivudine, entecavir and telbivudine) and two nucleotide analog prodrugs (adefovir dipivoxil and 
tenofovir disoproxil fumarate) [7,8]. HBV DNA polymerase is the main target for the nucleoside or 
nucleotide analogs. Drug combination therapy, as is now (standard care) for the treatment of HIV 
infections, may in the future also become adopted for the treatment of HBV infections. Various dual or 
triple drug combinations that have been used, with success, in the treatment of human Viruses 2010, 2                                       
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immunodeficiency virus (HIV) infection remain to be explored for their potential in the treatment of 
chronic hepatitis B. Other strategies whether targeted at the viral DNA polymerase or other molecular 
events in the HBV replication cycle have been reported, i.e., small interfering RNAs (siRNAs)   
{As was shown for many other viruses, siRNAs can be used to inhibit HBV replication in vitro [9-11] 
and in vivo [12]}, helioxanthin and related molecules, which inhibit viral nucleic acid and viral protein 
expression [13,14], heteroaryldihydropyrimidines (HAPs), such as BAY 41-4109 which inhibit 
nucleocapsid formation [15]; imino sugars (such as N-nonyl-deoxynojirimycin), which were found  
to suppress woodchuck hepatitis virus (WHV) replication in vivo (woodchucks) through   
inhibition of protein folding and trafficking [16]; nitazoxanide, tizoxanide and other thiazolides, which 
inhibit both hepatitis B virus and hepatitis C virus replication [17]; HBF-0259, a   
tetrahydro-tetrazolo-(1,5-a)-pyrimidine which specifically inhibits HBV surface antigen secretion [18]; 
β-LPA, a 2,6-diaminopurine analog containing a structure showing a mode of action that remains to be 
elucidated [19]; and a series of 7-deazaneplanocin A analogs for which, likewise, the mode of action 
remains to be elucidated [20]. Efficient inhibition of HBV replication has also been achieved by 
hammerhead ribozymes delivered by hepatitis delta virus [21]. 
2. HBV Replication Cycle 
Three types of particles are produced during replication of HBV: (i) Dane particles (infectious 
virions) [22], (ii) 20 nm HBsAg (hepatitis B surface antigen) spheres and (iii) variable length HBsAg 
filaments [23]. The latter two particles are non-infectious [24-26]. The virions contain a 3.2 kb relaxed 
circular (RC) DNA with four overlapping ORFs, namely P, C, S and X. The S gene encodes for three 
surface proteins: Large, Medium and Small HBsAg [27]. The polymerase is translated from the P 
ORF. The polymerase protein consists of four domains: terminal protein, spacer, RT and   
RNase H [28-30]. Of the seven subdomains of RT, domain C harbors the highly conserved YMDD 
motif, i.e., the catalytic site of the enzyme [31,32]. Infected hepatocytes also contain the hepatitis B 
core antigen (HBcAg). HBcAg, the excreted antigen (HBeAg), is encoded from the ORF C   
domain [33,34]. 
Following interaction with (an) unknown receptor(s), RC DNA from the virion is transported to the 
nucleus and converted into covalently closed circular DNA (cccDNA), while the nucleocapsids remain 
in the cytoplasm [35]. This DNA intermediate plays an important role in viral persistence and serves as 
a template for transcription by host RNA polymerase II to produce four mRNA transcripts of 3.5, 2.4, 
2.1 and 0.7 kb [36]. Importantly, cccDNA may be indicative of risk for HCC development, as   
Wong et al. have shown that tumor tissues had higher levels of cccDNA compared to non-tumor 
tissues [37].  
During core particle formation, encapsidation of the pgRNA takes place and reverse transcription 
starts [38]. The polymerase binds at the 5’ end of the pgRNA [39,40]. The original RNA template is 
degraded by RNAse H, except for a small RNA oligomer. Once (-) DNA synthesis is complete, a 
second translocation (the RNA primer translocation) to the 5’ end of DR2 occurs and (+) DNA 
synthesis starts using (-) DNA as template. Finally, circularization and extension of (variable length) 
(+) DNA strand terminates the DNA synthesis [39,40]. Viruses 2010, 2                                       
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In a minority of the virions [41], (+) DNA can either be (i) converted into cccDNA [42,43] or be (ii) 
integrated into chromosomal DNA [44-46]. The nucleocapsids are enclosed by envelope glycoproteins 
after budding into the endoplasmic reticulum and Golgi apparatus [47,48]. Mature virions are released 
through the secretory pathway. Alternatively, nucleocapsids are recycled back to the nucleus to 
maintain cccDNA levels (a process referred to as recycling pathway) [35]. For a more detailed 
description of HBV replication and gene function, see Ganem and Schneider [49]. Of all the steps in 
the HBV replication cycle, the reverse transcription can be considered as the most important target for 
current anti-HBV chemotherapy. 
3. Currently Approved (Licensed) Anti-HBV Drugs for the Treatment of CHB 
3.1. Lamivudine 
Lamivudine [(-)β-L-2’,3’-dideoxy-3’-thiacytidine (3TC)] (Figure 1A) has anti-HIV and anti-HBV 
properties. It was approved in 1998 by the FDA for the treatment of chronic hepatitis B infections. 
Lamivudine (Epivir-HBV
® or Zeffix
®) is administered daily at an oral dose of 100 mg. Within the cell, 
3TC is converted to its active form [3TC-triphosphate (3TC-TP)] [50]. Subsequently, 3TC-TP can act 
as (i) a chain terminator, after incorporation into the growing HBV DNA chain, or (ii) as a competitive 
inhibitor of deoxycytidine triphosphate (dCTP) at the level of the DNA polymerase. 3TC-TP inhibits 
viral DNA synthesis, but not mitochondrial DNA synthesis [51]. Lamivudine may interrupt the 
recycling of virions to the nucleus and suppress the formation of cccDNA [52]. 
Lamivudine treatment generally results in a three- to four-log drop in circulating HBV DNA levels, 
at least during the first months of treatment [53,54], and the HBV DNA levels after four weeks of 
lamivudine treatment may predict the long-term (five-year) outcome [55]. Concomitantly, HBeAg is 
cleared more rapidly from the circulation, and serum alanine aminotransferase (ALT) levels may 
normalize [53,54]. The virological and biochemical response may show a reduction of up to 74% and 
66%, respectively [56]. The drug is usually well tolerated [57,58]. Long-term lamivudine treatment 
may reduce the risk of developing cirrhosis and HCC [59]. 
However, lamivudine monotherapy rapidly leads to resistance development. Approximately 20% of 
HBeAg-positive patients develop resistance after one year, which increases up to 70% after five years 
[60,61] (Figure 2). The most common mutation is observed in the catalytic YMDD motif of the viral 
RT polymerase. The primary lamivudine-resistance mutation is M204V/I/S (in the viral RT 
polymerase) in the highly conserved YMDD motif. This is often combined with the L180M mutation 
[62] (Table 1). Lamivudine-resistant mutations can also occur outside the YMDD motif [63]. Although 
lamivudine-resistant HBV mutants remain highly sensitive to adefovir and tenofovir, cross-resistance 
has been observed towards other L-nucleoside analogs such as emtricitabine and telbivudine [64,65].  Viruses 2010, 2                                       
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Figure 1. Currently licensed anti-HBV drugs. (A) The L-nucleoside analog lamivudine; 
(B) the acyclic nucleoside phosphonate adefovir (PMEA), licensed as its prodrug adefovir 
dipivoxil [bis(pivaloyloxymethyl)ester of 9-(2-phosphonylmethoxyethyl)adenine or 
bis(POM)PMEA];  (C) the carbocyclic D-nucleoside analog entecavir; (D) the   
L-nucleoside analog β-L-2’-deoxythymidine (L-dT), or telbivudine; and   
(E) the acyclic nucleoside phosphonate tenofovir, licensed as its prodrug tenofovir 
disoproxil fumarate (TDF) [bis(isopropoxycarbonyloxymethyl) ester of   
9-(R)-2-(phosphonylmethoxypropyl)adenine or bis(POC)PMPA]. 
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Figure 2. Cumulative incidence of HBV resistance to lamivudine (LAM), adefovir (ADV), 
entecavir (ETV), telbivudine (LdT) and tenofovir (TDF) in published pivotal trials in 
NUC-naive patients. For method of calculation, see [61]. These trials included different 
populations, used different exclusion criteria and different follow-up endpoints [151]. 
 
 
3.2. Adefovir dipivoxil 
Adefovir (or PMEA [9-(2-phosphonylmethoxyethyl)adenine]) is an acyclic nucleoside phosphonate 
[66]. To increase its oral availability, PMEA has been esterified to its prodrug bis(POM)PMEA 
(Figure 1B). Adefovir dipivoxil was licensed as Hepsera
® in September 2002 for the treatment of 
CHB. It is administered orally at a dose of 10 mg daily. 
When PMEA enters the cell, it is phosphorylated twice by AMP kinase [67] to its active form 
PMEApp, which is incorporated into the growing HBV DNA chain, where it acts as (i) an obligatory 
chain terminator [68] and/or (ii) a competitive inhibitor of the natural substrate dATP. In addition to its 
anti-HBV activity, PMEApp has also demonstrated activity against other viruses, i.e., herpesviruses 
and retroviruses as well as bacteria producing adenylate cyclase toxins (e.g., B. anthracis, B. pertussis, 
P. aeruginosa) [69]. Treatment for 48 weeks with adefovir dipivoxil led to a decrease of both cccDNA 
and HBsAg levels in HBeAg-positive CHB patients; it has been estimated that it may take 
approximately 14.5 years to clear infected cells from cccDNA [70]. Viruses 2010, 2                                       
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Table 1. Currently licensed anti-HBV drugs as well as anti-HBV agents that are in clinical 
or preclinical development. Mutations that are/can be selected by these agents are 
indicated as well as the cross-resistance and sensitivity profiles of the drug-resistant 
variants. 
Agent  Mutation(s)  Cross-resistant to  Sensitive to 
Lamivudine rtM204I/S/V 
± rtL180M 
± rtV173C 
rTA181S plus rTM204I 
rT181T 
Other L-nucleoside 
analogs (Emtricitabine, 
Telbivudine) 
Adefovir 
Adefovir, Tenofovir, 
Entecavir ± MPA  
Adefovir  rtA181V/T and/or rtN236T    Lamivudine, 
Entecavir, 
Emtricitabine, 
Tenofovir 
Adefovir rtI233V    Tenofovir 
Entecavir  rtT184G or          + Lamivudine- 
rtS202I or               resistance 
rtM250V                mutations 
Lamivudine Adefovir 
Telbivudine rtM204I  Lamivudine   
Tenofovir  rtA194T + Lamivudine resistance 
mutations (rtM204V + rtL180M) 
  
Emtricitabine  rt204I/V ± rtL180M and rtV173C  Lamivudine   
 
Although treatment with 10 mg adefovir dipivoxil for 48 weeks resulted in a good anti-HBV 
response in CHB patients who were either negative or positive for HBeAg [71,72], efficacy was still 
improved if treatment was extended to 144 weeks in HBeAg-negative patients [73]. Adefovir dipivoxil 
at a dose of 10 mg/day has very few adverse effects; at higher doses, i.e., 30 or 60 mg/day   
(or 125 mg/day as initially used when the compound was developed for HIV treatment), the compound 
may be nephrotoxic [1,6,72]. Adefovir dipivoxil is being used at a dose as low as 10 mg/day, which 
may be considered as suboptimal [74]. Adefovir dipivoxil at a dose of 10 mg is well tolerated and had 
a similar side effect profile as placebo in phase III clinical trials. Nephrotoxicity has been reported in 
3% of patients with compensated liver disease after 4-5 years of continued adefovir dipivoxil therapy 
and in 6% of patients on the transplant waiting list [75,76]. 
The rate of development of adefovir resistance is much lower than for lamivudine monotherapy: not 
more than 6% after three years [73], and up to 18% after four years [77]. After five years of therapy, 
29% of the treated patients harbor adefovir-resistant HBV strains (as compared to 70% for   
lamivudine) [78]. 
Recent re-assessments estimated the cumulative probability of adefovir-resistant mutations at 12 
and 24 months to be 5% and 17%, respectively [79]. The main adefovir resistance is associated with 
the rtN236T and rtA181V/T mutations [80,81]. In lamivudine-resistant patients, emergence of the Viruses 2010, 2                                       
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rtN236T and rtA181V/T mutations is more common (Table 1), as compared to nucleoside-naïve 
patients [82]. 
Recently, three patients with primary adefovir resistance were described, which remained sensitive 
to tenofovir. The HBV variant already had a mutation before adefovir therapy was even initiated. 
When investigated more thoroughly, results showed that an rtI233V mutation was responsible for the 
adefovir resistance [83]. In general, adefovir-resistant HBV mutants remain susceptible to   
L-nucleoside analogs (i.e., lamivudine and entecavir) [84]. Adefovir resistance can be associated with 
viral rebound, hepatic flares and hepatic decompensation [85]. To prevent the emergence of adefovir 
resistance, adefovir should be combined with lamivudine, even in lamivudine-resistant patients [86]. 
Adefovir is active against lamivudine-resistant HBV strains (in liver transplant recipients) [76] as well 
as cirrhotic patients who failed on lamivudine therapy [87]. 
3.3. Entecavir 
Entecavir (Figure 1C) has been approved (licensed as Baraclude
®) in the United States for the 
treatment of CHB virus infections since April 2005. Its metabolism is comparable with that of the 
other nucleoside analogs. ETV is phosphorylated three times by human cellular kinases to its active 
form, ETV-TP. Intracellular accumulation occurs rapidly, its half-life is approximately 15 hours (as for 
lamivudine) [88] and it interferes with the HBV DNA polymerase in multiple ways: (i) it inhibits the 
priming of the polymerase, (ii) it has a high affinity for the HBV polymerase, (iii) it acts as a 
competitive inhibitor of dGTP (natural substrate) and (iv) it acts as a chain terminator two or three 
nucleotides downstream from its incorporation [89,90]. In fact, the incorporation of entecavir 
monophosphate into the DNA has at least three consequences: first, incorporation of the next 
nucleotide at position n + 1 following the incorporated entecavir monophosphate is compromised; 
second, strong pausing at position n + 3 suggests a delayed chain termination; and, third, the 
incorporated entecavir monophosphate can also act as a “base pair confounder” during synthesis of the 
second DNA strand [91]. 
Woodchucks chronically infected with woodchuck hepatitis virus (WHV), treated with 0.5 mg/kg 
ETV daily for eight weeks, showed decreased viremia levels. Long-term therapy with ETV, once a 
week, was also effective in maintaining low levels of viral load, decreasing cccDNA levels and viral 
antigens, expanding the life of the animals, and delaying the onset of HCC [92]. Two double-blind 
phase III studies with 715 HBeAg-positive and 648 HBeAg-negative nucleoside-naïve CHB patients 
revealed that entecavir therapy led to higher improved histological and virological values (like 
reduction in viral load, HBeAg loss and seroconversion) and reduced alanine aminotransferase levels 
compared with lamivudine [93,94]. Entecavir at a dose of 1 mg per day for 96 weeks of treatment 
resulted in continued clinical benefit in lamivudine-refractory HBeAg-positive CHB patients [95]. 
From clinical trials in China [96], Yao concluded that entecavir was superior to lamivudine as an  
anti-HBV drug [96], although in some instances, it showed only limited efficacy, with a “partial 
virologic response to adefovir therapy” [97].  
For patients with lamivudine failure, higher doses of ETV are recommended, as 10% of these 
patients might develop ETV resistance after two years [89]. The approved dose of entecavir for 
nucleoside-naïve patients is 0.5 mg daily orally and for lamivudine-resistant patients is 1.0 mg daily Viruses 2010, 2                                       
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orally. But even at the higher dose (1.0 mg/day), entecavir is no longer recommended for the treatment 
of lamivudine-resistant patients due to the high rates of entecavir resistance in such patients. 
The following mutations are specifically associated with ETV resistance: rtT184G, rtS202I, and 
rtM250V (Table 1) [98,99]. Two additional mutations (rtM204V and rTL180M) are associated with 
resistance to both lamivudine and entecavir (Table 1) [99]. The virologic response is closely related to 
the genotypic resistance [100], and although a high incidence of the emergence of entecavir-resistant 
mutants has been described among patients infected with lamivudine-resistant HBV [101], long-term 
monitoring has shown that entecavir resistance of HBV in nucleoside-naïve patients is rare through 
five years of therapy [102], thus proving a high genetic barrier of HBV drug resistance to entecavir. 
Surprisingly, in patients co-infected with HBV and HIV-1, entecavir led to the emergence of the 
lamivudine-resistant HIV-1 M184V reverse transcriptase variant [103,104], which on the one hand 
cautions against the use of entecavir in persons infected with both HIV-1 and HBV [105], but on the 
other hand suggests that entecavir may exhibit inhibitory activity against HIV under conditions of 
reduced viral challenge [106], although the HIV infection has no effect on the pharmacokinetics of 
entecavir in HBV-infected patients [107]. 
3.4. Telbivudine  
Telbivudine (Figure 1D) (for recent reviews see Keam [108] and Nash [109]) offers a new option 
for the treatment of CHB [110]: the compound is administered orally once daily as a single tablet of 
600 mg. The L-nucleoside telbivudine (β-L-2’-deoxythymidine or L-dT) is a specific anti-HBV agent. 
The 3’OH group is essential for anti-HBV activity; and removal or substitution of this group results in 
loss of activity [111]. In vitro studies with HepG2 cells and primary human hepatocytes have shown 
high phosphorylation rates of L-dT and L-dC [112]. Its active form L-dT-TP prefers to inhibit   
(+)-strand DNA synthesis and acts as a chain terminator [113]. It should be pointed out, however, that 
telbivudine, containing a 3’-hydroxyl function, does not have to act as an obligatory chain terminator.  
Data from phase I and phase II clinical trials have shown that different doses of telbivudine result in 
considerable reductions in HBV DNA levels after four weeks of treatment. Upon withdrawal of 
telbivudine the viral load dramatically increased [114]. A one year trial has shown that telbivudine 
decreased HBV DNA levels with >6 log10 compared with lamivudine (~4.5 log10) [115]. In   
HBeAg-positive, compensated CHB patients, L-dT gave an HBV DNA reduction of 6.30 log10 (44 
patients) after 24 weeks as compared to 4.97 log10 for adefovir dipivoxil (89 patients) [116].  
As compared to lamivudine, telbivudine demonstrated greater HBV DNA suppression in both 
HBeAg-negative and HBeAg-positive CHB patients [117]. Likewise, in Chinese patients with CHB, 
telbivudine, upon a year of treatment, provided greater antiviral and clinical efficacy than lamivudine 
[118]. During telbivudine treatment, non detectable serum HBV DNA after 24 weeks is the strongest 
predictor for optimal outcomes after two years [119]. 
The mutation rtM204I has been observed in patients who received telbivudine [115]. Data from 
Yang et al. showed that lamivudine-resistant strains are cross-resistant with several L-nucleosides, 
such as L-dT, L-dC and emtricitabine (Table 1) [64]. Therefore, telbivudine cannot be used to treat 
patients with lamivudine-resistant HBV. The phase III GLOBE trial showed that telbivudine, 
compared with lamivudine in HBeAg- positive and -negative patients, resulted in a higher antiviral and Viruses 2010, 2                                       
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clinical efficacy after two years of treatment [120]. From a pharmacokinetic point of view, telbivudine 
could, in principle, be combined with lamivudine or adefovir, because no drug interactions were 
observed [121].  
Against HBV genomes with known telbivudine-resistance mutations, M204I and L80I/M204I, 
telbivudine, lamivudine and entecavir lost 353- to >1000-fold activity, whereas adefovir and tenofovir 
exhibited no more than a 3- to 5-fold decrease in activity [122]. 
3.5. INF-α 
INF-α was the first substance licensed to treat CHB virus infections. Only 30% of the patients 
showed a successful response with loss of HBeAg, HBV DNA and normalization of ALT levels. 
Influenza-like side effects were observed. The mechanism of action of interferon is two-fold [123]:  
(i) it elicits antiviral activity (e.g., induction of 2’,5’-oligoadenylate synthetase), as well as   
(ii) immunomodulatory activity (e.g., increased expression of MHC I, and stimulation of CTLs). The 
recommended regimen of interferon α is 5 × 10
6 units administered daily or 10 2 × 10
6 units given 
three times a week subcutaneously for a period of four to six months [124]. At present, two types of 
interferon have been approved for CHB treatment: interferon α-2b (Intron A; Schering-Plough) and 
pegylated interferon α-2a (PEG-IFN; Pegasys; Roche). 
During 48 weeks, 814 patients with HBeAg-positive CHB received PEG-IFN plus placebo, PEG-
IFN plus lamivudine, or lamivudine alone, and were followed up for 24 weeks. This study 
demonstrated that PEG-IFN - with or without lamivudine treatment - led to higher percentages of 
HBeAg seroconversion, HBV DNA suppression and HBsAg seroconversion (this was not observed 
with lamivudine monotherapy) and, thus, PEG-IFN 2α provides a significant improved efficiency over 
lamivudine [125]. In the HBeAg-negative CHB patients, PEG-IFN α-2a may offer a sustained 
response, resulting in HBsAg clearance three years after treatment [126]. 
PEG-IFN α-2b is effective against HBeAg-positive CHB, but combinations with lamivudine [127] 
or ribavirin [128] resulted in no additional benefit. In contrast, a recent combination treatment study in 
CHB patients by Wursthorn et al., using PEG-IFN α-2b and adefovir, showed a strong reduction in 
HBV DNA, cccDNA and HBsAg levels [129]. Peginterferon α-2b has been shown to be safe and 
effective in HBeAg-positive CHB patients with advanced fibrosis, and, hence, these patients should 
not be excluded from PEG-IFN treatment [130]. 
3.6. Tenofovir disoproxil fumarate 
Tenofovir disoproxil fumarate (TDF) (Viread
®) (Figure 1E) was approved by the FDA for the 
treatment of AIDS in 2001 and for the treatment of CHB in 2008. The efficacy of TDF against   
wild-type as well as lamivudine-resistant HBV strains [131] was demonstrated in patients co-infected 
with HIV and HBV. In vitro studies revealed that the combination of tenofovir with emtricitabine 
resulted in additive to synergistic effect. Combinations with lamivudine, entecavir or telbivudine 
resulted in additive effects [132]. Tenofovir undergoes two efficient phosphorylations to its active 
form, PMPApp, which has a long half-life (95 h) [133]. It functions as a chain terminator and 
represents a poor substrate for cellular DNA polymerases α,  β and ε [134,135]. To increase oral Viruses 2010, 2                                       
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absorption, tenofovir is esterified to its bis(isopropyloxycarbonyloxymethyl)ester   
[tenofovir disoproxil, bis(POC)PMPA] (Figure 1E).  
At a daily dose of 300 mg it has a superior antiviral efficacy (with a similar safety profile), as 
compared with adefovir dipivoxil at a daily dose of 10 mg, following 48 weeks of treatment [136]. 
Several studies have corroborated that TDF is more potent than adefovir dipivoxil in the treatment of 
CHB [137-140]. TDF is highly efficacious in the treatment of advanced liver disease in patients   
co-infected with HBV and HIV who developed resistance to lamivudine [141]. Woodchuck studies 
using different concentrations of TDF administered once a day for four weeks showed a good safety 
profile and reductions in viremia levels [142].  
The rtA194T mutation in vitro and in HBV/HIV co-infected patients showed TDF resistance in the 
presence of lamivudine mutations rtL180M and rtM204V (Table 1) [143]. The rTA194T polymerase 
mutations are associated with partial tenofovir resistance and negatively impacts replication 
competence of HBV constructs. Viral replication, however, can be restored to wild-type levels, if these 
polymerase mutations occur together with precore or basic core promoter substitutions as found in 
HBeAg-negative hepatitis B [144]. Patients with HBeAg-negative chronic HBV infection may 
therefore be at particular risk when developing resistance to tenofovir. TDF offers an important 
alternative for patients with low lamivudine or adefovir dipivoxil responses [145].  
4. Novel anti-HBV agents  
4.1. Emtricitabine  
Emtricitabine or (-)FTC has been licensed for the treatment of HIV infections. The mechanism of 
action is similar to that of lamivudine. Following three phosphorylations, (-)FTC acts as (i) a chain 
terminator for the nascent HBV DNA chain and/or (ii) as a competitive inhibitor of its natural 
substrate dCTP. Additionally, (-)FTC-TP is a weak inhibitor of cellular and mitochondrial DNA 
polymerases. At different doses, emtricitabine, when given to chronically WHV-infected woodchucks, 
caused reduced viremia levels [146].  
Studies in humans have shown that 200 mg (-)FTC (the optimal dose) daily for two years gave a 
safe antiviral profile but a resistance rate of 18% [147] (versus 20% for lamivudine after one year). 
The (-)FTC resistance mutations observed were rtM204I/V ± rtL180M and rtV173L (Table 1). A study 
comparing the combination of the standard dose (-)FTC and 10 mg clevudine and (-)FTC alone for 24 
weeks showed no significant difference between both groups, but the combination group had a 
significantly greater virological and biochemical response at 24 weeks post-treatment. The prolonged 
anti-HBV activity of clevudine was also observed in the combination group, as well as in phase II 
clinical trials where clevudine monotherapy was administered [148,149]. Possible side effects 
observed with (-)FTC include lactic acidosis and hepatoxicity [150]. In addition, flare-ups of HBV 
infection after withdrawal of (-)FTC have also been reported [150]. 
4.2. Clevudine 
Clevudine corresponds to L-FMAU (2’-fluoro-5-methyl-β-L-arabinofuranosyluracil). Serum HBV 
DNA levels were undetectable by PCR at the end of treatment in 59% of HBe Ag-positive and in 92% Viruses 2010, 2                                       
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of HBe Ag-negative patients [151,152]. A unique feature of clevudine is the durability of viral 
suppression, persisting for up to 24 weeks after withdrawal of treatment. Nonetheless, clevudine has 
not been shown to increase the rate of HBe Ag seronconversion compared to placebo controls. Clinical 
trials found that the rtA181T mutation, which is associated with resistance to lamivudine and adefovir 
could be selected after only 24 weeks of clevudine treatment [151]. Clevudine was then reported to be 
associated with myopathy in patients who had been treated for longer than 24 weeks, and 
mitochondrial toxicity was documented in some patients [153,154]. These observations have led to the 
discontinuation of the global phase III clinical trials with clevudine. 
5. Recommendations 
Clinical practice guidelines for the management of chronic hepatitis B have been published by the 
European Association for the Study of the Liver (EASL) [155], the American Association for the 
Study of Liver Diseases (AASLD) [156] and the Asian Pacific Association for the Study of the Liver 
(APASL) [157,158]; the latter being specific for the immunomodulatory therapy of CHB. 
Rates of HBe seroconversion, undetectable HBV DNA and normal ALT at one year of therapy with 
(pegylated) interferon, lamivudine, adefovir dipivoxil, entecavir, telbivudine and tenofovir disoproxil 
fumarate in HBe Ag-positive patients are presented in Figure 3A, and those of undetectable HBV 
DNA and normal ALT in HBe Ag-negative patients are presented in Figure 3B (both sets of data taken 
from [155]). The most potent drugs, i.e., tenofovir or entecavir, should be used as first-line 
monotherapies [155]. 
Rates of resistance at up to five years of treatment are shown in Figure 2. Resistance is associated 
with prior treatment with lamivudine, adefovir, telbivudine or emtricitabine. Resistance should be 
identified as early as possible before clinical breakthrough (increased ALT) by means of HBV DNA 
monitoring, and, if possible, identification of the resistance mutations. Clinical and virological studies 
have demonstrated the benefit of an early treatment adaptation as soon as viral load increases 
[159,160]. 
Table 2 shows cross-resistance data for the most frequent drug-resistant HBV variants [161]. 
Although the long-term safety of the indicated combination is unknown, it is recommended [155] to  
(i) in the case of lamivudine resistance, to add tenofovir (or adefovir if tenofovir is not available);  
(ii) in the case of adefovir resistance, to switch to tenofovir (if available; or if an N236T mutation is 
present, to add lamivudine, entecavir or telbivudine, or if an A181T/V mutation is present, to add 
entecavir); (iii) in the case of telbivudine resistance, add tenofovir (or adefovir if tenofovir is not 
available); (v) resistance to tenofovir has not been described so far [61,155]. 
The APASL [157] guidelines stipulated that for patients who develop lamivudine resistance, add-on 
adefovir therapy is indicated, and that for lamivudine-naïve patients who develop drug resistance while 
on adefovir, add-on or switching to lamivudine, telbivudine or entecavir is indicated, while for patients 
who develop drug resistance while on telbivudine, add-on adefovir therapy is indicated [157]. 
 Viruses 2010, 2                                       
 
 
1291
Figure 3. (A) Rates of HBe seroconversion, undetectable HBV DNA and normal ALT at 
one year of therapy with pegylated interferon alpha-2a (PEG-IFN), lamivudine (LAM), 
adefovir (ADV), entecavir (ETV), telbivudine (LdT) and tenofovir (TDF) in HBeAg-
positive patients with CHB in randomized clinical trials. (B) Rates of undetectable HBV 
DNA and normal ALT at one year of therapy with PEG-IFN, LAM, ADV, ETV, LdT and 
TDF in HBeAg-negative patients with CHB in randomized clinical trials. The trials in (A) 
and (B) used different HBV DNA assays and they were not head-to-head comparisons for 
all the drugs; thus, these numbers are only indicative and should be considered with 
caution [155].  
A. 
 
B. 
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Table 2. Cross-resistance data for the most frequently resistant HBV variants.   
The amino-acid substitution profiles are shown in the left column and the level of 
susceptibility is given for each drug: S (sensitive), I (intermediate/reduced susceptibility),  
R (resistant) [161]. 
HBV variant  Level of susceptibility 
 Lamivudine  Telbivudine  Entecavir  Adefovir  Tenofovir 
Wild-type S  S  S  S  S 
M204I R  R  I  S  S 
L180M + M204V  R  R  I  S  S 
A181T/V I  S  S  R  S 
N236T S  S  S  R  I 
L180M + M204I/S/V ± 
I169T ± V173L ± M250V 
R R  R  S  S 
L180M + M204I/S/V ± 
T184G ± S202I/G 
R R  R  S  S 
 
6. Concluding Remarks 
Besides interferon, five licensed products are currently available for the treatment of chronic HBV 
infection: (i) lamivudine, (ii) adefovir (dipivoxil), (iii) entecavir, (iv) telbivudine and (v) tenofovir 
(disoproxil fumarate) (see Table 3). Lamivudine monotherapy is associated with higher resistance  
(up to 70% after five years) than adefovir (29% after five years) or telbivudine   
(9-22% after two years) [162].  
Table 3. Anti-HBV agents. 
Generic name  Brand name  Manufacturer  Date of FDA approval 
Anti-HBV drugs approved by the US Food and Drug Administration 
Interferon alfa-2b  Intron A  Schering-Plough  13 July 1992 
Lamivudine, 3TC  Epivir-HBV  GlaxoSmithKline  9 December 1998 
Adefovir dipivoxil  Hepsera  Gilead Sciences  20 September 2002 
Entecavir  Baraclude  Bristol-Myers Squibb  30 March 2005 
Peginterferon alfa-2a  Pegasys  Roche  13 May 2005 
Telbivudine  Tyzeka  Idenix  25 October 2006 
Tenofovir disoproxil fumarate  Viread  Gilead Sciences  11 August 2008 
 
Entecavir resistance is rare in naïve individuals (<1% after four years), but increases over time in 
lamivudine-resistant patients (43% after four years). According to Papatheodoridis et al. [162], the Viruses 2010, 2                                       
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8-174. 
best strategy for long-term therapy in chronic HBV infection has yet to be established. This paper was 
published on 8 March 2008 before TDF was formally licensed for use in the treatment of CHB. 
Entecavir and tenofovir may represent the drugs of choice for the treatment of CHB as they couple 
high potency with a high genetic barrier [163], but entecavir monotherapy certainly is not the 
treatment of choice for lamivudine-resistant HBV patients [150]. 
Cross-trial comparisons of treatment outcomes, comparing pegylated interferon α-2a, lamivudine 
(LAM), adefovir (ADV) dipivoxil, entecavir (ETV), telbivudine (LDT) and tenofovir disoproxil 
fumarate (TDF) in terms of three parameters, (i) HBV DNA reduction, (ii) HBeAg seroconversion and 
(iii) rate of resistance have indicated that ETV and TDF (both as monotherapy) are superior to the 
other treatment regimens (also as monotherapy) [164]. In the near future, improvements in HBV 
therapy will likely involve combinations of potent nucleoside analogs (such as entecavir or 
telbivudine) with a potent nucleotide such as tenofovir. In the longer term future HBV therapy may or 
should aim at achieving a gain in post-treatment durable response rates by the development of HBV 
drugs with a novel mechanism of action (such as for example encapsidation inhibitors) or 
immunomodulatory approaches, that can be used in combination with nucleos(t)ides. 
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